FAF
HZNP

Fjarde Ap-fonden’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Fjarde Ap-fonden’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-79,584
Closed -$9.21M – 561
2023
Q3 		$9.21M Sell
79,584
-3,800
-5% -$408K 0.12% 174
2023
Q2 		$8.58M Buy
83,384
+1,700
+2% +$179K 0.11% 206
2023
Q1 		$8.91M Sell
81,684
-9,200
-10% -$1.02M 0.12% 189
2022
Q4 		$10.3M Sell
90,884
-1,600
-2% -$133K 0.15% 159
2022
Q3 		$7.38M Hold
92,484
– – 0.09% 220
2022
Q2 		$7.38M Buy
92,484
+16,200
+21% +$1.53M 0.09% 220
2022
Q1 		$8.03M Buy
76,284
+4,384
+6% +$427K 0.08% 265
2021
Q4 		$7.75M Buy
71,900
+600
+0.8% +$65.5K 0.07% 294
2021
Q3 		$7.81M Sell
71,300
-2,700
-4% -$280K 0.07% 277
2021
Q2 		$6.93M Sell
74,000
-4,400
-6% -$405K 0.06% 320
2021
Q1 		$7.22M Sell
78,400
-700
-0.9% -$59.1K 0.07% 298
2020
Q4 		$5.79M Buy
+79,100
New +$5.88M 0.05% 334

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.05B AUM 19.75% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Fjarde Ap-fonden's HZNP Position: Q4 2023 in Review

Fjarde Ap-fonden sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 79,584 shares — an estimated $9.21M sold.

Fjarde Ap-fonden first reported a position in HZNP in Q4 2020 and held it in 12 quarters. The position peaked at $10.3M in Q4 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Fjarde Ap-fonden reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Fjarde Ap-fonden sold 79,584 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $9.21M.
  • Fjarde Ap-fonden first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020 and held it in 12 quarters.
  • Fjarde Ap-fonden's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $10.3M in Q4 2022.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Fjarde Ap-fonden's 13F filing for Q4 2023, filed 14 Feb 2024.